NCT04453280

Antibody Detection in COVID-19 Cured Patients (SARS-CoV-2-CZ-Immunity)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 695 (actual)
• Sponsor: Institute of Health Information and Statistics of the Czech Republic · Other Government
• Sex: All
• Age: 8 Years
• Healthy volunteers: Not accepted

Summary

The aim of the SARS-CoV-2-CZ-Immunity study is to determine the time profile of the presence of antibodies against SARS-CoV-2 in blood plasma by quantification of antibodies or performing a rapid test in COVID-19 cured patients.

Detailed description

COVID-19 is caused by a new type of coronavirus called SARS-CoV-2. It is a highly infectious disease, manifested mainly by fever, respiratory problems, muscle pain, and fatigue. However, despite the publication of hundreds of papers in the literature, fundamental information about the spread and course of the disease is still lacking in COVID-19. One of such key information is the time profile of the presence of antibodies against SARS-CoV-2 after the disease. The SARS-CoV-2-CZ-Immunity study is aiming at the determination of the time profile of the presence of antibodies against SARS-CoV-2 in blood plasma by quantification of antibodies or performing a rapid test in COVID-19 cured patients.

Conditions

• COVID
• SARS-CoV-2

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Quantitative analysis of anti-SARS-CoV-2-antibodies	Plasma sampling will be collected and archived for subsequent quantitative analysis of anti-SARS-CoV-2 antibodies - IgG, IgM and IgA.
DIAGNOSTIC_TEST	SARS-CoV-2 diagnostic rapid test	The rapid test detects the presence of antibodies against SARS-CoV-2 by the immunochromatographic reaction.

Timeline

• Start date: 2020-05-18
• Primary completion: 2020-06-03
• Completion: 2020-06-03
• First posted: 2020-07-01
• Last updated: 2020-07-01

Locations

1 site across 1 country: Czechia